- Article
Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer
- Jeyshka M. Reyes-González,
- Blanca I. Quiñones-Díaz,
- Yasmarie Santana,
- Perla M. Báez-Vega,
- Daniel Soto,
- Fatima Valiyeva,
- María J. Marcos-Martínez,
- Ricardo J. Fernández-de Thomas and
- Pablo E. Vivas-Mejía
Despite good responses to first-line treatment with platinum-based combination chemotherapy, most ovarian cancer patients will relapse and eventually develop platinum-resistant disease with poor prognosis. Although reports suggest that integrin-linke...